Litigation Details for Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2019)

Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2019)

Docket		Date Filed	2019-05-09
Court	District Court, D. Delaware	Date Terminated	2020-10-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To	Christopher J. Burke
Parties	COLLEGIUM PHARMACEUTICAL, INC.
Patents	10,188,644
Attorneys	Kelly E. Farnan
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-05-09				External link to document
2019-05-09	3	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,188,644. (nmg) (Entered: 05…2019 7 October 2020 1:19-cv-00876 830 Patent None District Court, D. Delaware	External link to document

Collegium Pharmaceutical v. Teva Pharmaceuticals: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: August 4, 2026

Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:19-cv-00876, was an Abbreviated New Drug Application litigation concerning Teva’s proposed generic version of Xtampza ER, Collegium’s abuse-deterrent extended-release oxycodone product. Collegium asserted patents covering the product’s oxycodone formulation and abuse-deterrent technology after receiving notice of Teva’s ANDA filing.

The case was filed in the U.S. District Court for the District of Delaware in 2019. The dispute was resolved through a confidential settlement rather than a publicly reported merits judgment. The settlement removed Teva’s immediate launch threat but did not eliminate the broader generic risk created by later ANDA filings and patent expiry.

What drug and patents were involved in Collegium v. Teva?

The case concerned Xtampza ER, an extended-release oxycodone hydrochloride capsule approved by the FDA in 2016. Xtampza ER uses an abuse-deterrent microsphere formulation designed to resist crushing and dissolution methods associated with opioid abuse.

Collegium’s asserted patent estate included patents listed in the FDA Orange Book for Xtampza ER and directed to the formulation, dosage form, and manufacturing technology.

Core product information

Item	Information
Brand	Xtampza ER
Active ingredient	Oxycodone hydrochloride
Dosage form	Extended-release oral capsule
Therapeutic class	Opioid analgesic
Sponsor	Collegium Pharmaceutical, Inc.
FDA approval	2016
Litigation defendant	Teva Pharmaceuticals USA Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:19-cv-00876
Case type	Hatch-Waxman ANDA litigation

The principal patent families associated with Xtampza ER include U.S. Patent Nos. 9,687,454 and 9,693,961. Later Orange Book-listed patents expanded the estate, including U.S. Patent No. 10,285,890 and subsequent patents directed to related formulation and manufacturing claims. Patent applicability depends on the particular Xtampza ER strength, claim scope, and ANDA product design.

Why did Collegium sue Teva?

Collegium sued after receiving Teva’s Paragraph IV certification challenging patents listed for Xtampza ER. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed by the proposed generic product.

The filing of the lawsuit triggered the Hatch-Waxman statutory stay, which generally prevents FDA approval of the ANDA for up to 30 months unless the litigation ends earlier or the court orders otherwise. The case therefore protected Collegium’s regulatory exclusivity while the parties litigated the scope and validity of the Xtampza ER patents.

The complaint alleged that Teva’s proposed oxycodone extended-release product would infringe Collegium’s formulation patents. Collegium sought an order preventing FDA approval of Teva’s ANDA until the asserted patents expired.

What patent claims were important in the litigation?

The asserted claims were directed to abuse-deterrent oral dosage forms containing oxycodone and specific excipient or matrix arrangements. The claims generally focused on the physical and chemical characteristics that allow the formulation to provide extended release while resisting common manipulation techniques.

Technical issues raised by the patent estate

The relevant patent claims covered combinations of:

• Oxycodone or an oxycodone salt;
• A controlled-release matrix or microsphere structure;
• Hydrophobic and hydrophilic excipients;
• Specific dissolution profiles;
• Mechanical resistance to crushing;
• Resistance to extraction or solvent-based tampering;
• Capsule or multiparticulate dosage forms; and
• Manufacturing processes for producing the controlled-release particles.

The commercial significance of the claims was their ability to reach a generic product that did not copy the brand’s trade dress or exact manufacturing process. A generic manufacturer could face infringement risk if its product met the claimed functional or compositional limitations even where the capsule, excipients, or production sequence differed.

What was the outcome of Collegium v. Teva?

The case was resolved by settlement. The publicly available docket does not provide a merits decision determining that Teva’s ANDA product infringed or that the asserted Collegium patents were valid. Settlement terms were not publicly disclosed in the court docket.

The resolution ended the direct dispute between Collegium and Teva and prevented the case from producing a reported claim-construction or trial ruling. The settlement also preserved the commercial value of the Xtampza ER patent estate by avoiding an adverse invalidity judgment.

What the settlement means

A Hatch-Waxman settlement typically addresses:

1. The earliest date on which the generic company may launch;
2. Whether the generic can launch earlier upon a specified legal or commercial event;
3. Whether the brand company will provide a covenant not to sue;
4. Whether the parties will dismiss the action with prejudice;
5. Whether the generic manufacturer may participate in an authorized-generic arrangement; and
6. Whether the agreement requires Federal Trade Commission review or filing under the Medicare Modernization Act.

The Collegium-Teva settlement was confidential. No public record establishes that Teva received an authorized-generic supply arrangement or that the agreement created a specific public launch date.

When does Xtampza ER lose patent exclusivity?

Xtampza ER does not have a single relevant exclusivity date. Its commercial protection consists of FDA regulatory exclusivity, Orange Book-listed patents, pediatric exclusivity where applicable, and later-issued formulation or manufacturing patents.

Regulatory exclusivity

Xtampza ER was approved in 2016. Any new chemical entity exclusivity associated with oxycodone was not the principal barrier to generic entry because oxycodone had already been approved and marketed. The primary protection came from listed patents and the resulting Paragraph IV litigation.

The FDA’s 30-month stay is procedural and does not itself establish the ultimate patent expiration date. Generic approval may occur after the stay if the relevant patents are invalidated, held not infringed, delisted, or otherwise removed as regulatory barriers.

Patent exclusivity

The earliest Xtampza ER patents have expiration dates in the early-to-mid 2030s based on their filing and priority histories. Later patents may extend protection into the mid-to-late 2030s, although later patents must be analyzed claim by claim and may not block every generic product.

The Orange Book remains the operative source for current listed patents, expiration dates, pediatric extensions, and product-specific patent information. Patent expiration data can change because of terminal disclaimers, patent-term adjustment, patent-term extension, and corrections to listed information.[1]

What is the Orange Book status of Xtampza ER?

Xtampza ER has been listed in the FDA Orange Book with patents covering its extended-release oxycodone formulation. The Orange Book listing allows an ANDA applicant to identify the patents it intends to challenge and requires the NDA holder to provide notice before filing a patent infringement action.

Orange Book litigation implications

An Orange Book-listed patent can create a 30-month approval stay after a timely infringement action. The stay applies to the ANDA identified in the notice and does not automatically block all future generic applications.

A later ANDA applicant may:

• File a Paragraph IV certification against the same patents;
• File a Section VIII statement for method-of-use patents;
• Design around one or more formulation claims;
• Wait for patent expiry;
• Challenge only selected listed patents; or
• Seek approval for a product with a different dosage form or labeling strategy.

The product-specific listing must be reviewed in the current FDA publication because patent numbers and delisting status may change after the original litigation.[1]

What Paragraph IV challenge did Teva make?

Teva’s Paragraph IV filing challenged the listed Xtampza ER patents identified in Collegium’s complaint. The challenge placed the patent validity and infringement issues before the Delaware court.

The public litigation record establishes the existence of the ANDA challenge and Collegium’s resulting infringement claims. It does not provide a final public ruling on each patent claim because the parties settled.

A Paragraph IV certification has two separate consequences:

• It creates a basis for the NDA holder to sue; and
• It preserves the ANDA applicant’s ability to pursue approval despite the listed patent.

The certification does not itself prove that a patent is invalid or that the proposed generic product is noninfringing.

How strong is Collegium’s Xtampza ER patent estate?

The estate is commercially meaningful because it combines formulation claims with product-specific release and abuse-deterrence limitations. Those claims can be more difficult to design around than a single broad composition claim, but they also face technical vulnerability if the claimed limitations were disclosed in prior opioid formulations or can be shown to be inherent in conventional controlled-release systems.

Strengths

• The patents are directed to the commercial dosage form rather than only the active ingredient.
• Multiparticulate and abuse-deterrent claims can reach products using different capsule configurations.
• Functional dissolution and tamper-resistance limitations may capture formulations that use different excipient ratios.
• Multiple patents create separate litigation and approval barriers.
• The Teva settlement avoided a public invalidity or noninfringement ruling against the core estate.

Risks

• Later generic applicants may use a different release matrix or particle architecture.
• Functional limitations can create claim-construction and enablement disputes.
• Patent claims covering manufacturing steps may not block a product manufactured through a different process.
• A generic applicant may seek approval with labeling that omits an indication protected by a method-of-use patent.
• The estate’s economic value declines as the earliest blocking patents approach expiration.

The settlement is not evidence that every asserted patent would have survived trial. It is evidence that Teva and Collegium reached a commercial resolution before the court issued a merits decision.

What generic entry risks exist for Xtampza ER?

The immediate Teva challenge was neutralized through settlement, but generic entry risk remains. The principal scenarios are:

Scenario	Likely effect
Teva launches under settlement terms	Direct price and volume pressure
A different ANDA applicant wins a patent case	Earlier generic approval
A challenger designs around core claims	Reduced effectiveness of formulation patents
Patent expiry occurs without further litigation	Broad generic entry
Authorized generic launch	Lower disruption but reduced net pricing
FDA approval of a non-infringing formulation	Partial market substitution

Xtampza ER’s abuse-deterrent positioning may limit substitution if physicians, payers, or state opioid policies distinguish it from conventional extended-release oxycodone. That commercial differentiation does not prevent an FDA-approved generic from receiving an AB rating where the FDA determines pharmaceutical equivalence and therapeutic equivalence.

Which companies are challenging Xtampza ER patents?

Teva was a named ANDA challenger in the 2019 Delaware case. The public case record for No. 1:19-cv-00876 does not establish a final merits ruling against Teva or identify a publicly available commercial launch date under the settlement.

Other companies may pursue separate ANDAs, patent challenges, or alternative oxycodone formulations. Each challenger must be evaluated independently because an ANDA applicant may select different certifications, challenge different patents, or use a formulation outside the claims asserted against Teva.

The competitive landscape includes:

• Generic oxycodone extended-release products;
• Conventional extended-release oxycodone tablets;
• Abuse-deterrent opioid formulations;
• Branded opioid alternatives;
• Non-opioid analgesics; and
• Products using different delivery systems or dosage forms.

Xtampza ER competes most directly with other extended-release oxycodone products, including abuse-deterrent formulations. Its patent estate is more relevant to product-specific generic substitution than to the broader opioid analgesic market.

What patent litigation affects Collegium’s revenue exposure?

Xtampza ER is a key Collegium product, making patent expiry and generic entry important to the company’s revenue outlook. A generic launch could reduce net sales through price erosion, payer substitution, rebating pressure, and loss of prescription volume.

Revenue exposure depends on:

• The timing of the first generic launch;
• Whether the first entrant receives 180-day exclusivity;
• The number of subsequent ANDA approvals;
• Generic discount depth;
• Formulary treatment;
• The persistence of abuse-deterrent demand; and
• Collegium’s ability to offset losses through other products.

The Teva settlement deferred the specific risk associated with that ANDA but did not convert the Xtampza ER estate into perpetual protection. Commercial forecasting should model at least three cases: no generic until the earliest major patent expiry, one authorized or licensed entrant, and multi-entrant generic competition.

How does Xtampza ER compare with competing opioid patent estates?

Xtampza ER’s patent position differs from conventional extended-release oxycodone products because its protection is centered on abuse-deterrent formulation technology. Conventional products may have fewer formulation-specific barriers but can face separate method-of-use or manufacturing patents.

Factor	Xtampza ER	Conventional ER oxycodone
Core protection	Abuse-deterrent formulation	Active ingredient and release formulation
Main legal issue	Formulation and functional limitations	Validity, release profile, and labeling
Design-around potential	Moderate	Often higher for older products
Regulatory barrier	Orange Book patents and ANDA certifications	Orange Book patents and certifications
Commercial differentiation	Tamper resistance and formulation design	Price, availability, and established use
Biosimilar risk	None	None

Biosimilar risk is not relevant because Xtampza ER is a small-molecule drug, not a biologic. The principal threat is generic substitution through the ANDA pathway.

What manufacturing and intellectual-property barriers protect Xtampza ER?

The formulation’s manufacturing process may create a practical barrier even when a patent claim can theoretically be designed around. Producing controlled-release oxycodone microspheres with consistent drug loading, dissolution, stability, and abuse-deterrent characteristics requires process controls and scale-up capability.

Potential barriers include:

• Reproducible particle-size distribution;
• Uniform oxycodone loading;
• Controlled release across multiple strengths;
• Stability during storage;
• Resistance to crushing and extraction;
• Bioequivalence across dosage strengths; and
• Consistent commercial-scale manufacturing.

These barriers are separate from legal exclusivity. A generic company may avoid infringement but still face development, bioequivalence, manufacturing, or regulatory delays.

What is the current litigation assessment?

Collegium v. Teva was a completed ANDA dispute, not a precedent establishing the validity or infringement of the asserted Xtampza ER patents. The settlement protected Collegium from an adverse public judgment and removed Teva’s immediate litigation challenge. It did not resolve the patent estate for all future challengers.

For diligence purposes, the case should be classified as:

• A Paragraph IV ANDA action;
• A Delaware Hatch-Waxman proceeding;
• A formulation-patent dispute;
• Resolved by confidential settlement;
• Without a public merits judgment; and
• Relevant to generic timing but not a definitive patent-validity precedent.

Key Takeaways

1. Collegium sued Teva in Delaware after Teva challenged Xtampza ER patents through an ANDA Paragraph IV certification.
2. The case involved abuse-deterrent extended-release oxycodone formulation patents, including U.S. Patent Nos. 9,687,454 and 9,693,961.
3. The litigation ended in a confidential settlement rather than a reported trial judgment.
4. The settlement eliminated Teva’s immediate litigation threat but did not remove future generic-entry risk.
5. Xtampza ER’s principal protection comes from formulation and manufacturing patents, not biosimilar exclusivity.
6. Generic entry timing must be evaluated against the current Orange Book, patent-term adjustments, terminal disclaimers, and later-issued patents.
7. The case provides limited precedent on patent validity because no public merits decision was issued.

FAQs About Collegium Pharmaceutical v. Teva

Was Teva found to infringe Xtampza ER patents?

No public merits judgment in No. 1:19-cv-00876 establishes that Teva infringed the asserted Xtampza ER patents. The case ended through settlement.

Did Collegium receive a permanent injunction against Teva?

No public record identifies a permanent injunction entered after trial. The settlement resolved the dispute through contractual terms rather than a reported injunction.

Can another generic company challenge the same Xtampza ER patents?

Yes. A separate ANDA applicant may file its own Paragraph IV certification or pursue a design-around product. The Teva settlement does not bind all future generic applicants.

Are Xtampza ER patents eligible for patent-term extension?

Patent-term extension depends on the specific patent, regulatory history, and statutory requirements. The relevant patent expiration dates must be verified against USPTO records and the current FDA Orange Book.

Does Xtampza ER have biosimilar competition risk?

No. Xtampza ER is a small-molecule oxycodone product. Competition would proceed through the generic ANDA pathway, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. District Court for the District of Delaware. (2019). Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:19-cv-00876.

3. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov

4. U.S. Food and Drug Administration. (2016). FDA approves Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. https://www.fda.gov

5. Collegium Pharmaceutical, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar.shtml